Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial☆Xiaohua Wu, Mansoor Raza Mirza, Jihong Liu et al.|Annals of Oncology|2021Cited by 212
Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trialXiaohua Wu, Linjuan Zeng, Jihong Liu et al.|Nature Medicine|2024Cited by 41